Serum cytokeratin-19 fragment (Cyfra 21-1) is a prognostic indicator for epithelial ovarian cancer. 2014

Hua-Hsi Wu, and Peng-Hui Wang, and Jiun-Yih Yeh, and Yi-Jen Chen, and Ming-Shyen Yen, and Rui-Lan Huang, and Yueh-Ju Tsai, and Chiou-Chung Yuan
Department of Obstetrics and Gynecology, Taipei Veterans General Hospital and National Yang-Ming University, Taipei, Taiwan; Institute of Clinical Medicine, National Yang-Ming University, Taipei, Taiwan.

OBJECTIVE Cytokeratin 19 is significant for indicating cancer cells, and Cyfra 21-1 is a fragment of cytokeratin 19. This retrospective study was designed to define the prognostic value of serum Cyfra 21-1 in epithelial ovarian cancers (EOC). METHODS Serum Cyfra 21-1 concentration was obtained from 42 patients with EOC prior to treatment. Various prognostic aspects were examined using univariable and multivariable analyses. The standard serum marker cancer antigen 125 was measured simultaneously and compared in this analysis. RESULTS Serum levels of both Cyfra 21-1 and cancer antigen 125 were associated with positive retroperitoneal lymph nodes and platinum resistance; higher levels of Cyfra 21-1 (3.0 ng/mL as the cut-off) were associated with shorter disease-free survival (16 months vs. 28 months, p = 0.001) and overall survival (29 months vs. 41 months, p = 0.007) than lower levels. Further univariable analysis showed that Cyfra 21-1, poor differentiation, and retroperitoneal lymph node metastasis were related to platinum resistance and mortality. Multivariable analysis indicated retroperitoneal lymph node metastasis and serum Cyfra 21-1 were independent risk factors for both disease-free survival and overall survival. CONCLUSIONS The pretreatment level of serum Cyfra 21-1 had remarkable prognostic significance for EOC, indicating poor survival when it was elevated above 3.0 ng/mL.

UI MeSH Term Description Entries
D008198 Lymph Nodes They are oval or bean shaped bodies (1 - 30 mm in diameter) located along the lymphatic system. Lymph Node,Node, Lymph,Nodes, Lymph
D008207 Lymphatic Metastasis Transfer of a neoplasm from its primary site to lymph nodes or to distant parts of the body by way of the lymphatic system. Lymph Node Metastasis,Lymph Node Metastases,Lymphatic Metastases,Metastasis, Lymph Node
D008565 Membrane Proteins Proteins which are found in membranes including cellular and intracellular membranes. They consist of two types, peripheral and integral proteins. They include most membrane-associated enzymes, antigenic proteins, transport proteins, and drug, hormone, and lectin receptors. Cell Membrane Protein,Cell Membrane Proteins,Cell Surface Protein,Cell Surface Proteins,Integral Membrane Proteins,Membrane-Associated Protein,Surface Protein,Surface Proteins,Integral Membrane Protein,Membrane Protein,Membrane-Associated Proteins,Membrane Associated Protein,Membrane Associated Proteins,Membrane Protein, Cell,Membrane Protein, Integral,Membrane Proteins, Integral,Protein, Cell Membrane,Protein, Cell Surface,Protein, Integral Membrane,Protein, Membrane,Protein, Membrane-Associated,Protein, Surface,Proteins, Cell Membrane,Proteins, Cell Surface,Proteins, Integral Membrane,Proteins, Membrane,Proteins, Membrane-Associated,Proteins, Surface,Surface Protein, Cell
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009375 Neoplasms, Glandular and Epithelial Neoplasms composed of glandular tissue, an aggregation of epithelial cells that elaborate secretions, and of any type of epithelium itself. The concept does not refer to neoplasms located in the various glands or in epithelial tissue. Epithelial Cell Neoplasms,Glandular Cell Neoplasms,Epithelial Neoplasms,Glandular Neoplasms,Glandular and Epithelial Neoplasms,Neoplasms, Epithelial,Neoplasms, Glandular,Neoplasms, Glandular Epithelial,Cell Neoplasm, Epithelial,Cell Neoplasm, Glandular,Cell Neoplasms, Epithelial,Epithelial Cell Neoplasm,Epithelial Neoplasm,Epithelial Neoplasm, Glandular,Glandular Cell Neoplasm,Glandular Epithelial Neoplasm,Glandular Epithelial Neoplasms,Glandular Neoplasm,Neoplasm, Epithelial,Neoplasm, Epithelial Cell,Neoplasm, Glandular,Neoplasm, Glandular Cell,Neoplasm, Glandular Epithelial
D010051 Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS. Cancer of Ovary,Ovarian Cancer,Cancer of the Ovary,Neoplasms, Ovarian,Ovary Cancer,Ovary Neoplasms,Cancer, Ovarian,Cancer, Ovary,Cancers, Ovarian,Cancers, Ovary,Neoplasm, Ovarian,Neoplasm, Ovary,Neoplasms, Ovary,Ovarian Cancers,Ovarian Neoplasm,Ovary Cancers,Ovary Neoplasm
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077216 Carcinoma, Ovarian Epithelial A malignant neoplasm that originates in cells on the surface EPITHELIUM of the ovary and is the most common form of ovarian cancer. There are five histologic subtypes: papillary serous, endometrioid, mucinous, clear cell, and transitional cell. Mutations in BRCA1, OPCML, PRKN, PIK3CA, AKT1, CTNNB1, RRAS2, and CDH1 genes are associated with this cancer. Epithelial Ovarian Cancer,Epithelial Ovarian Carcinoma,Ovarian Cancer, Epithelial,Ovarian Epithelial Cancer,Ovarian Epithelial Carcinoma,Cancer, Epithelial Ovarian,Cancer, Ovarian Epithelial,Carcinoma, Epithelial Ovarian,Epithelial Cancer, Ovarian,Epithelial Carcinoma, Ovarian,Epithelial Ovarian Cancers,Epithelial Ovarian Carcinomas,Ovarian Carcinoma, Epithelial,Ovarian Epithelial Cancers,Ovarian Epithelial Carcinomas

Related Publications

Hua-Hsi Wu, and Peng-Hui Wang, and Jiun-Yih Yeh, and Yi-Jen Chen, and Ming-Shyen Yen, and Rui-Lan Huang, and Yueh-Ju Tsai, and Chiou-Chung Yuan
January 1997, European urology,
Hua-Hsi Wu, and Peng-Hui Wang, and Jiun-Yih Yeh, and Yi-Jen Chen, and Ming-Shyen Yen, and Rui-Lan Huang, and Yueh-Ju Tsai, and Chiou-Chung Yuan
October 2019, The Journal of dermatology,
Hua-Hsi Wu, and Peng-Hui Wang, and Jiun-Yih Yeh, and Yi-Jen Chen, and Ming-Shyen Yen, and Rui-Lan Huang, and Yueh-Ju Tsai, and Chiou-Chung Yuan
September 2020, Cancers,
Hua-Hsi Wu, and Peng-Hui Wang, and Jiun-Yih Yeh, and Yi-Jen Chen, and Ming-Shyen Yen, and Rui-Lan Huang, and Yueh-Ju Tsai, and Chiou-Chung Yuan
January 1999, Anticancer research,
Hua-Hsi Wu, and Peng-Hui Wang, and Jiun-Yih Yeh, and Yi-Jen Chen, and Ming-Shyen Yen, and Rui-Lan Huang, and Yueh-Ju Tsai, and Chiou-Chung Yuan
July 1994, Oncology reports,
Hua-Hsi Wu, and Peng-Hui Wang, and Jiun-Yih Yeh, and Yi-Jen Chen, and Ming-Shyen Yen, and Rui-Lan Huang, and Yueh-Ju Tsai, and Chiou-Chung Yuan
January 2006, Journal of hepato-biliary-pancreatic surgery,
Hua-Hsi Wu, and Peng-Hui Wang, and Jiun-Yih Yeh, and Yi-Jen Chen, and Ming-Shyen Yen, and Rui-Lan Huang, and Yueh-Ju Tsai, and Chiou-Chung Yuan
January 1995, Anticancer research,
Hua-Hsi Wu, and Peng-Hui Wang, and Jiun-Yih Yeh, and Yi-Jen Chen, and Ming-Shyen Yen, and Rui-Lan Huang, and Yueh-Ju Tsai, and Chiou-Chung Yuan
December 1994, Gynecologic oncology,
Hua-Hsi Wu, and Peng-Hui Wang, and Jiun-Yih Yeh, and Yi-Jen Chen, and Ming-Shyen Yen, and Rui-Lan Huang, and Yueh-Ju Tsai, and Chiou-Chung Yuan
January 2004, The International journal of biological markers,
Hua-Hsi Wu, and Peng-Hui Wang, and Jiun-Yih Yeh, and Yi-Jen Chen, and Ming-Shyen Yen, and Rui-Lan Huang, and Yueh-Ju Tsai, and Chiou-Chung Yuan
January 1993, Cancer research,
Copied contents to your clipboard!